CN1203089C - 新化合物 - Google Patents

新化合物 Download PDF

Info

Publication number
CN1203089C
CN1203089C CNB95196643XA CN95196643A CN1203089C CN 1203089 C CN1203089 C CN 1203089C CN B95196643X A CNB95196643X A CN B95196643XA CN 95196643 A CN95196643 A CN 95196643A CN 1203089 C CN1203089 C CN 1203089C
Authority
CN
China
Prior art keywords
phenyl
nmr
alkoxy
preparation
apci
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
CNB95196643XA
Other languages
English (en)
Chinese (zh)
Other versions
CN1168675A (zh
Inventor
大木秀德
富岛昌纪
山田明
高杉寿
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Yamanouchi Pharmaceutical Co Ltd
Original Assignee
Fujisawa Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26305774&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CN1203089(C) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from GB9420425A external-priority patent/GB9420425D0/en
Priority claimed from GBGB9508745.8A external-priority patent/GB9508745D0/en
Application filed by Fujisawa Pharmaceutical Co Ltd filed Critical Fujisawa Pharmaceutical Co Ltd
Publication of CN1168675A publication Critical patent/CN1168675A/zh
Application granted granted Critical
Publication of CN1203089C publication Critical patent/CN1203089C/zh
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/50—Cyclic peptides containing at least one abnormal peptide link
    • C07K7/54—Cyclic peptides containing at least one abnormal peptide link with at least one abnormal peptide link in the ring
    • C07K7/56—Cyclic peptides containing at least one abnormal peptide link with at least one abnormal peptide link in the ring the cyclisation not occurring through 2,4-diamino-butanoic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
CNB95196643XA 1994-10-07 1995-09-29 新化合物 Expired - Lifetime CN1203089C (zh)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
GB9420425A GB9420425D0 (en) 1994-10-07 1994-10-07 New compound
GB9420425.2 1994-10-07
GB9508745.8 1995-04-28
GBGB9508745.8A GB9508745D0 (en) 1995-04-28 1995-04-28 New compound

Publications (2)

Publication Number Publication Date
CN1168675A CN1168675A (zh) 1997-12-24
CN1203089C true CN1203089C (zh) 2005-05-25

Family

ID=26305774

Family Applications (1)

Application Number Title Priority Date Filing Date
CNB95196643XA Expired - Lifetime CN1203089C (zh) 1994-10-07 1995-09-29 新化合物

Country Status (26)

Country Link
US (2) US6107458A (cg-RX-API-DMAC7.html)
EP (1) EP0788511B1 (cg-RX-API-DMAC7.html)
JP (2) JP2897427B2 (cg-RX-API-DMAC7.html)
KR (1) KR100353303B1 (cg-RX-API-DMAC7.html)
CN (1) CN1203089C (cg-RX-API-DMAC7.html)
AR (1) AR041770A1 (cg-RX-API-DMAC7.html)
AT (1) ATE229541T1 (cg-RX-API-DMAC7.html)
AU (1) AU696949B2 (cg-RX-API-DMAC7.html)
BR (2) BR9504791B1 (cg-RX-API-DMAC7.html)
CA (1) CA2202058C (cg-RX-API-DMAC7.html)
DE (2) DE122008000025I2 (cg-RX-API-DMAC7.html)
DK (1) DK0788511T3 (cg-RX-API-DMAC7.html)
ES (1) ES2187575T3 (cg-RX-API-DMAC7.html)
FI (1) FI119988B (cg-RX-API-DMAC7.html)
FR (1) FR08C0028I2 (cg-RX-API-DMAC7.html)
HU (1) HU228151B1 (cg-RX-API-DMAC7.html)
IL (1) IL115484A (cg-RX-API-DMAC7.html)
LU (1) LU91452I2 (cg-RX-API-DMAC7.html)
MX (1) MX9702531A (cg-RX-API-DMAC7.html)
NL (1) NL300352I2 (cg-RX-API-DMAC7.html)
NO (2) NO328483B1 (cg-RX-API-DMAC7.html)
OA (1) OA10475A (cg-RX-API-DMAC7.html)
PT (1) PT788511E (cg-RX-API-DMAC7.html)
RU (1) RU2165423C2 (cg-RX-API-DMAC7.html)
TR (1) TR199501229A2 (cg-RX-API-DMAC7.html)
WO (1) WO1996011210A1 (cg-RX-API-DMAC7.html)

Families Citing this family (61)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5696084A (en) * 1996-08-16 1997-12-09 Abbott Laboratories Amino-lipopetide antifungal agents
AUPO371596A0 (en) * 1996-11-19 1996-12-12 Fujisawa Pharmaceutical Co., Ltd. New compound
AUPO381496A0 (en) * 1996-11-25 1996-12-19 Fujisawa Pharmaceutical Co., Ltd. New compound
US6291680B1 (en) * 1997-06-18 2001-09-18 Fujisawa Pharmaceutical Co., Ltd. Production process
CA2320416A1 (en) * 1998-02-09 1999-08-12 Fujisawa Pharmaceutical Co., Ltd. New compound
AU756792B2 (en) * 1998-02-09 2003-01-23 Fujisawa Pharmaceutical Co., Ltd. New compound
ES2251976T3 (es) * 1999-02-11 2006-05-16 Emisphere Technologies, Inc. Compuestos y composiciones de oxadiazol para aportar agentes activos.
US7084279B1 (en) * 1999-02-11 2006-08-01 Emisphere Technologies Inc. Oxadiazole compounds and compositions for delivering active agents
AUPP999799A0 (en) * 1999-04-27 1999-05-20 Fujisawa Pharmaceutical Co., Ltd. New compound
AUPQ066399A0 (en) * 1999-05-31 1999-06-24 Fujisawa Pharmaceutical Co., Ltd. Antifungal combination use
TWI233805B (en) * 1999-07-01 2005-06-11 Fujisawa Pharmaceutical Co Stabilized pharmaceutical composition in lyophilized form as antifungal agent
CA2380176A1 (en) 1999-07-27 2001-02-01 Aventis Pharma Deutschland Gmbh Novel cyclohexapeptide compounds, processes for their production and their use as a pharmaceutical
AUPQ462399A0 (en) * 1999-12-13 2000-01-13 Fujisawa Pharmaceutical Co., Ltd. New use
TWI250992B (en) 2000-02-21 2006-03-11 Astellas Pharma Inc Polypeptide compounds for the prophylactic and/or therapeutic treatment of infectious diseases caused by pathogenic microorganisms
ES2191516B1 (es) * 2000-07-28 2005-01-01 Consejo Superior De Investigaciones Cientificas Antibioticos antifungicos de naturaleza peptidica inhibidores de la germinacion y el crecimiento de hongos fitopatogenos.
AUPQ938700A0 (en) * 2000-08-14 2000-09-07 Fujisawa Pharmaceutical Co., Ltd. Antifungal combination use
ATE452637T1 (de) 2001-01-29 2010-01-15 Shionogi & Co Arzneipräparat, das als wirkstoff 5-methyl-1- phenyl-2-(1h)-pyridon enthält
JP2005053782A (ja) * 2001-08-31 2005-03-03 Fujisawa Pharmaceut Co Ltd 環状リポペプチド化合物の新規結晶
AU2003217676B2 (en) 2002-02-22 2009-06-11 Takeda Pharmaceutical Company Limited Active agent delivery systems and methods for protecting and administering active agents
US7199248B2 (en) 2002-08-08 2007-04-03 Astellas Pharma Inc. Process
AU2003903205A0 (en) * 2003-06-23 2003-07-10 Fujisawa Pharmaceutical Co., Ltd. New compound
WO2005018743A1 (en) * 2003-07-22 2005-03-03 Theravance, Inc. Use of an echinocandin antifungal agent in combination with a glycopeptide antibacterial agent
AU2004273029A1 (en) * 2003-09-05 2005-03-24 Merck & Co., Inc. Stationary phases and a purification process using the stationary phases
WO2005028438A1 (ja) * 2003-09-22 2005-03-31 Banyu Pharmaceutical Co., Ltd. 新規ピペリジン誘導体
US7476673B2 (en) * 2003-12-30 2009-01-13 Allergan, Inc. Disubstituted chalcone oximes as selective agonists of RARγ retinoid receptors
US20050261365A1 (en) * 2004-05-20 2005-11-24 The Scripps Research Institute Transthyretin stabilization
CN101084212A (zh) 2004-09-20 2007-12-05 泽农医药公司 杂环衍生物及其作为硬脂酰CoA去饱和酶介导剂的用途
BRPI0515482A (pt) 2004-09-20 2008-07-22 Xenon Pharmaceuticals Inc derivados heterocìclicos e seus usos como agentes terapêuticos
EP2289510A1 (en) 2004-09-20 2011-03-02 Xenon Pharmaceuticals Inc. Heterocyclic derivatives for the treatment of diseases mediated by stearoyl-coa desaturase enzymes
AR051092A1 (es) 2004-09-20 2006-12-20 Xenon Pharmaceuticals Inc Derivados heterociclicos y su uso como inhibidores de la estearoil-coa
MX2007003332A (es) 2004-09-20 2007-06-05 Xenon Pharmaceuticals Inc Derivados heterociclicos y su uso como inhibidores de estearoil-coa-desaturasa.
TW200626155A (en) 2004-09-20 2006-08-01 Xenon Pharmaceuticals Inc Heterocyclic derivatives and their use as therapeutic agents
JP5043668B2 (ja) 2004-09-20 2012-10-10 ゼノン・ファーマシューティカルズ・インコーポレイテッド 複素環誘導体および治療薬としてのそれらの使用
KR20070067165A (ko) * 2004-10-13 2007-06-27 피티씨 테라퓨틱스, 인크. 넌센스 변이 억제용 화합물, 및 이의 사용 방법
JP2009513563A (ja) 2005-06-03 2009-04-02 ゼノン・ファーマシューティカルズ・インコーポレイテッド ヒトのステアロイル−ＣｏＡデサチュラーゼ阻害剤としてのアミノチアゾール誘導体
WO2007043401A1 (ja) * 2005-10-07 2007-04-19 Kissei Pharmaceutical Co., Ltd. 含窒素複素環化合物およびそれを含有する医薬組成物
CN101516387B (zh) * 2006-07-26 2014-06-04 桑多斯股份公司 卡泊芬净制剂
US8853392B2 (en) 2007-06-03 2014-10-07 Vanderbilt University Benzamide mGluR5 positive allosteric modulators and methods of making and using same
PL2786992T3 (pl) 2007-08-13 2018-04-30 Monsanto Technology Llc Kompozycje i sposoby zwalczania nicieni
AU2008319977A1 (en) * 2007-10-29 2009-05-07 Astellas Pharma Inc. Polypeptide compound
US8034806B2 (en) 2007-11-02 2011-10-11 Vanderbilt University Bicyclic mGluR5 positive allosteric modulators and methods of making and using same
CA2729212C (en) * 2008-06-24 2014-04-01 Irm Llc Compounds and methods for modulating g protein-coupled receptors
US9394340B2 (en) 2009-03-24 2016-07-19 Cadila Healthcare Limited Purification process for lipopeptides
BR112013023531A2 (pt) * 2011-04-04 2016-12-06 Xellia Pharmaceuticals Aps processo de um único vaso para a fabricação de micafungina ou de um sal desta
BR112013026420A2 (pt) 2011-04-20 2020-11-03 Xellia Pharmaceuticals Aps método de produção de um sal de micafungina farmaceuticamente aceitável
CN102775476B (zh) 2011-05-12 2015-01-07 上海天伟生物制药有限公司 一种米卡芬净钠盐的制备方法
EP2709609B1 (en) 2011-05-17 2017-10-04 Shionogi & Co., Ltd. Heterocyclic compounds
EP2763971B1 (en) 2011-09-09 2016-06-08 Sandoz AG Preparation of micafungin intermediates
CN102659930B (zh) 2012-03-30 2014-04-23 上海天伟生物制药有限公司 一种高纯度环肽类物质的晶体及其制备方法和用途
CN102627689B (zh) 2012-03-30 2014-08-06 上海天伟生物制药有限公司 一种环肽类化合物的水合物及其制备方法和用途
CN102627688B (zh) 2012-03-30 2014-12-31 上海天伟生物制药有限公司 一种高纯度环肽化合物及其制备方法和用途
EP3150621A4 (en) * 2014-05-29 2017-12-27 Shanghai Techwell Biopharmaceutical Co., Ltd Composition of cyclic peptide compound, preparation method for same, and uses thereof
CN104861044B (zh) * 2014-05-29 2019-03-01 上海天伟生物制药有限公司 一种环肽类化合物的溶剂合物及其制备方法和用途
WO2016056023A2 (en) * 2014-10-07 2016-04-14 Alaparthi Lakshmi Prasad Intermediates and processes to prepare micafungin
CA2937365C (en) 2016-03-29 2018-09-18 F. Hoffmann-La Roche Ag Granulate formulation of 5-methyl-1-phenyl-2-(1h)-pyridone and method of making the same
FI3554474T3 (fi) 2016-12-16 2024-02-21 Baxter Int Mikafungiinikoostumuksia
EP3485873A1 (en) 2017-11-17 2019-05-22 Cadila Healthcare Limited Stable pharmaceutical injectable compositions of micafungin
CN113087775B (zh) * 2018-05-31 2022-07-08 杭州中美华东制药有限公司 米卡芬净钠新晶型ii及其制备方法
WO2020013116A1 (ja) * 2018-07-10 2020-01-16 京都薬品工業株式会社 Ｐｔｐ－１ｂ阻害剤およびその用途
CN110734408A (zh) * 2019-10-22 2020-01-31 重庆康乐制药有限公司 一种米卡芬净类衍生物侧链中间体的制备方法
CN115785226A (zh) * 2021-09-09 2023-03-14 上海天伟生物制药有限公司 一种棘白菌素药物杂质及其制备、纯化方法和应用

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SU1574603A1 (ru) * 1988-08-11 1990-06-30 Ивановский Химико-Технологический Институт Способ получени мезо-тетраарилоктаметилпорфиринов
FI912873A7 (fi) * 1990-06-18 1991-12-19 Fujisawa Pharmaceutical Co Uusi polypeptidiyhdiste ja menetelmä sen valmistamiseksi
MY136593A (en) * 1992-03-19 2008-10-31 Lilly Co Eli Cyclic peptide antifungal agents and process for preparation thereof

Also Published As

Publication number Publication date
CA2202058C (en) 2007-11-06
FR08C0028I1 (cg-RX-API-DMAC7.html) 2008-08-15
CN1168675A (zh) 1997-12-24
LU91452I2 (fr) 2008-08-04
HUT77736A (hu) 1998-07-28
NO971544D0 (no) 1997-04-04
KR970707150A (ko) 1997-12-01
JPH10507174A (ja) 1998-07-14
NO971544L (no) 1997-06-04
FI971397L (fi) 1997-05-27
ES2187575T3 (es) 2003-06-16
IL115484A (en) 2000-07-16
KR100353303B1 (ko) 2003-01-15
NL300352I1 (nl) 2008-08-01
NO2010016I2 (no) 2011-10-17
EP0788511A1 (en) 1997-08-13
DE122008000025I1 (de) 2008-08-21
NO2010016I1 (no) 2010-08-16
DE122008000025I2 (de) 2011-02-17
JP3518665B2 (ja) 2004-04-12
PT788511E (pt) 2003-04-30
ATE229541T1 (de) 2002-12-15
AU696949B2 (en) 1998-09-24
JP2897427B2 (ja) 1999-05-31
DE69529172D1 (de) 2003-01-23
US6107458A (en) 2000-08-22
JPH10324695A (ja) 1998-12-08
NO328483B1 (no) 2010-03-01
NL300352I2 (nl) 2008-11-03
EP0788511B1 (en) 2002-12-11
DK0788511T3 (da) 2003-03-31
BR9504791B1 (pt) 2010-10-05
CA2202058A1 (en) 1996-04-18
FI119988B (fi) 2009-05-29
BR9504791A (pt) 1996-10-22
US6265536B1 (en) 2001-07-24
TR199501229A2 (tr) 1996-07-21
MX9702531A (es) 1997-06-28
OA10475A (en) 2002-04-08
HK1004136A1 (en) 1998-11-20
IL115484A0 (en) 1996-01-19
RU2165423C2 (ru) 2001-04-20
DE69529172T2 (de) 2003-04-17
FR08C0028I2 (cg-RX-API-DMAC7.html) 2009-11-20
FI971397A0 (fi) 1997-04-04
HU228151B1 (en) 2012-12-28
AU3578095A (en) 1996-05-02
BRPI9504791B8 (pt) 2019-12-31
AR041770A1 (es) 2005-06-01
WO1996011210A1 (en) 1996-04-18

Similar Documents

Publication Publication Date Title
CN1203089C (zh) 新化合物
CN1240713C (zh) 化合物
CN1040541C (zh) 新型多肽化合物的制备方法
CN1225471C (zh) 具有生长激素释放特性的化合物
CN1289500C (zh) 氮杂双环化合物,它们的制备方法以及它们作为药物的应用,特别地作为抗菌剂的应用
CN1198839C (zh) 作为凝血酶抑制剂的新的二肽脒类
CN1027271C (zh) 正斯塔提尼及正环斯塔提尼多肽的制备方法
CN1038939C (zh) 肽类化合物的制备方法
CN1192773C (zh) 环胺ccr3拮抗剂
CN1247544C (zh) 带有杂芳基磺酰基侧链的邻氨基苯甲酰胺及其作为抗心律失常活性物质的用途
CN1057306C (zh) 新的多肽化合物及其制备方法
CN1198804C (zh) 酰胺化合物及其用途
CN1066660A (zh) 新的肽化合物及其制备方法
CN1568187A (zh) 2h－2,3－二氮杂萘－1－酮和其使用方法
CN1327443A (zh) 取代的酰苯胺化合物
CN1118595A (zh) 氨茴酸衍生物
CN1276785A (zh) N－烷酰基苯丙氨酸衍生物
CN1237978A (zh) N－(芳基/杂芳基)氨基酸衍生物、包括这些衍生物的药用组合物以及用这些化合物抑制β－淀粉样肽释放和或其合成的方法
CN1281430A (zh) 芳酰基苯丙氨酸衍生物
CN1474809A (zh) 氰基吡咯烷衍生物
CN1469871A (zh) 作为生长激素促分泌素的取代的二肽
CN1247542A (zh) 丝氨酸蛋白酶抑制剂
CN1560051A (zh) 取代吡唑化合物
CN1764648A (zh) 作为组蛋白脱乙酰酶(hdac)抑制剂的异羟肟酸衍生物
CN1204889C (zh) 粘附受体拮抗剂

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
C56 Change in the name or address of the patentee

Owner name: ASTELLAS PHARMA INC.

Free format text: FORMER NAME OR ADDRESS: FUJISAWA PHARMACEUTICAL CO., LTD.

CP03 Change of name, title or address

Address after: Tokyo, Japan

Patentee after: Yamanouchi Pharma Co., Ltd.

Address before: Osaka City, Osaka of Japan

Patentee before: Fujisawa Pharmaceutical Co., Ltd.

CX01 Expiry of patent term

Granted publication date: 20050525

EXPY Termination of patent right or utility model